IL151987A0 - Nuclear factor kb inducing factor - Google Patents

Nuclear factor kb inducing factor

Info

Publication number
IL151987A0
IL151987A0 IL15198701A IL15198701A IL151987A0 IL 151987 A0 IL151987 A0 IL 151987A0 IL 15198701 A IL15198701 A IL 15198701A IL 15198701 A IL15198701 A IL 15198701A IL 151987 A0 IL151987 A0 IL 151987A0
Authority
IL
Israel
Prior art keywords
nfif
polypeptides
methods
factor
nfkb
Prior art date
Application number
IL15198701A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL151987A0 publication Critical patent/IL151987A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15198701A 2000-03-31 2001-04-02 Nuclear factor kb inducing factor IL151987A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (1)

Publication Number Publication Date
IL151987A0 true IL151987A0 (en) 2003-04-10

Family

ID=26244722

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15198701A IL151987A0 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor
IL151987A IL151987A (en) 2000-03-31 2002-09-29 NUCLEIC ACID ENCODING NUCLEAR FACTOR kb INDUCING FACTOR (nfif), POLYPEPTIDE AND A MEDICAMENT COMPRISING THE SAME
IL198132A IL198132A0 (en) 2000-03-31 2009-04-16 Nuclear factor kb inducing factor

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL151987A IL151987A (en) 2000-03-31 2002-09-29 NUCLEIC ACID ENCODING NUCLEAR FACTOR kb INDUCING FACTOR (nfif), POLYPEPTIDE AND A MEDICAMENT COMPRISING THE SAME
IL198132A IL198132A0 (en) 2000-03-31 2009-04-16 Nuclear factor kb inducing factor

Country Status (14)

Country Link
EP (1) EP1290023B1 (enExample)
JP (1) JP4750999B2 (enExample)
KR (1) KR100811571B1 (enExample)
AT (1) ATE486089T1 (enExample)
AU (1) AU4793101A (enExample)
CA (1) CA2404688C (enExample)
DE (1) DE60143354D1 (enExample)
DK (1) DK1290023T3 (enExample)
IL (3) IL151987A0 (enExample)
MX (1) MXPA02009481A (enExample)
NO (1) NO331972B1 (enExample)
NZ (1) NZ521786A (enExample)
PT (1) PT1290023E (enExample)
WO (1) WO2001074900A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1997037020A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1358347A2 (en) * 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
EP1358349A2 (en) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
IL151987A (en) 2010-12-30
AU4793101A (en) 2001-10-15
HK1053312A1 (en) 2003-10-17
DK1290023T3 (da) 2011-02-14
EP1290023A2 (en) 2003-03-12
KR100811571B1 (ko) 2008-03-10
NO331972B1 (no) 2012-05-14
JP2003529360A (ja) 2003-10-07
KR20020087459A (ko) 2002-11-22
WO2001074900A9 (en) 2003-03-06
CA2404688C (en) 2012-07-31
CA2404688A1 (en) 2001-10-11
JP4750999B2 (ja) 2011-08-17
WO2001074900A3 (en) 2002-05-02
WO2001074900A2 (en) 2001-10-11
PT1290023E (pt) 2011-01-05
NO20024656D0 (no) 2002-09-27
IL198132A0 (en) 2011-08-01
EP1290023B1 (en) 2010-10-27
MXPA02009481A (es) 2004-05-14
NZ521786A (en) 2004-07-30
NO20024656L (no) 2002-11-28
DE60143354D1 (de) 2010-12-09
ATE486089T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
SE9800836D0 (sv) New Compounds
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
ATE232396T1 (de) Oxydiertes thymosin beta 4
NO20035773L (no) Ny konstruert superantigen for human terapi
NO20033862D0 (no) Fremgangsmåter for forebyggelse eller behandling av inflammatoriske eller autoimmune sykdommer ved administrering av integrin-alfa-beta3-antagonister
EP1578347A4 (en) COMPOSITIONS AND METHODS FOR DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNES DISEASES
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
AU4347701A (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
FR2834889B1 (fr) Forme pharmaceutique solide orodispersible
IL198132A0 (en) Nuclear factor kb inducing factor
GB0101124D0 (en) DNA element and assoc
WO2002058681A8 (fr) Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1.
GB9930075D0 (en) Medicaments
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
WO1999014322A3 (en) Allelic variant of human stat3
ATE368733T1 (de) Bfit (brown fat inducible thioesterase) polypeptide und polynukleotide und ihre verwendung
BR0109721A (pt) Fator de indução do fator kb nuclear
DE50208267D1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
ITLI20020003A1 (it) Custodia per totanaia e simili idonea alla sicurezza antinfortunistica del pescatore e ad un uso facile di attrezzi da pesca
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
ITBO20000360A0 (it) Apparecchiatura di elettrostimolazione del corpo umano .
WO1999037774A3 (en) Differentiation-associated sequences and methods of use therefor